Document is current

Article History

Received: 2 February 2025

Accepted: 11 April 2025

First Online: 22 April 2025

Declarations

:

: FC has received honoraria and/or travel grants from Astra Zeneca, Daiichi, Gilead, MSD, Merck Serono, Nutricia, Novartis outside the submitted work. ML has received payment of congress fees from Daiichi, Lilly, MSD, Pfizer, GSK, Novartis, Mundi pharma, EISAI; and has undertaken consultancy for MSD, Astra-Zeneca, Pierre Fabre, GSK, Lilly and Seagen outside the submitted work. NO has received payment of congress fees from Pfizer, Gillead and Lilly; and has undertaken consultancy for Gilead and Astra Zeneca outside the submitted work. The other authors report no potential conflicts of interest.

: The present study follows the French reference methodology MR-004 and was approved by the Institutional Scientific and Ethics Committees of Henri Becquerel Center (registering order N°2406B).

: All patients signed a consent form allowing the conservation and use of their biological samples. No patient objected to the use of the anonymous data generated for research purposes, according to MR-004 methodology.

: This manuscript does not contain any individual personal data.